TriSalus Life Sciences swaps board members

WESTMINSTER — Arjun Desai has stepped down from the board of directors at TriSalus Life Sciences Inc. (Nasdaq: TLSI), a Westminster-based oncology company, and is being replaced by Michael Stansky.

“Mr. Stansky brings 40 years of investment management and healthcare experience, advising and serving on the boards of numerous public and private healthcare companies. Most recently, Mr. Stansky served as a Managing Director at Tudor Investment Corporation, a global investment management firm, where he helped form the firm’s equity investment group and was responsible for long/short equity, crossover, and venture investments,” TriSalus said in a news release. “Prior to Tudor, Mr. Stansky was an analyst and portfolio manager at Wellington Management Company.”

Stansky currently serves on the board of Insightec Ltd. and Momentis Surgical, and his past board positions include Mako Surgical Corp., OrthoSensor Inc. and Transmedics Inc..

TriSalus has developed a technology platform to treat hard-to-reach liver and pancreatic tumors.

Share on Facebook on LinkedIn